Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Jan 1, 2026.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.040a, Telisotuzumab vedotin-tllv (Emrelis™)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Jan 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage has updated its policy for Telisotuzumab vedotin-tllv (Emrelis™), a new pharmacy medication. This policy establishes coverage criteria and billing requirements for this newly approved drug treatment.

Action Required

Action needed

By January 1, 2026: Review the complete MA08.040a policy at the source URL to understand coverage criteria, prior authorization requirements, and billing procedures for Telisotuzumab vedotin-tllv (Emrelis™). Update pharmacy billing protocols and staff training as needed based on the full policy details.

Related policy hubs

Independence Blue Cross policies Oncology Hematology